<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01837615</url>
  </required_header>
  <id_info>
    <org_study_id>NL39583.018.12</org_study_id>
    <nct_id>NCT01837615</nct_id>
  </id_info>
  <brief_title>Assessment of Photopill Capsule Treatment for Safety and Feasibility in Ulcerative Proctitis</brief_title>
  <acronym>Photopill</acronym>
  <official_title>Assessment of the Photopill Capsule Treatment for Safety and Feasibility in Patients With Ulcerative Proctitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Photopill Medical Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low Level Light therapy (LLLT) has been used for tissue healing in many mucosal diseases that
      involve wounds, ulcers and inflammation, oral chemotherapy-induced mucositis in particular.
      Likewise IBD is characterized by chronic tissue inflammation, tissue damage and ulcerations
      in various extents. Therefore we hypothesize that LLLT might be effective in treating IBD and
      the Photopill capsule was developed for this purpose.

      An open-label, interventional, clinical trial was designed for assessment of the safety and
      feasibilty of the Photopill capsule treatment in patients with mild to moderate Ulcerative
      Proctitis.

      Primary endpoints being: safety reflected by the number and severity of adverse events and
      mucosal appearance at sigmoidoscopies day 14, day 28, day 42 compared to baseline condition.

      Furthermore clinical and biochemical parameters are monitored during the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>day 0-42</time_frame>
    <description>Any adverse events reported by subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>day 0,14,28,42</time_frame>
    <description>serum CRP, serum Hb/Ht, fecal Calprotectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Questionnaires</measure>
    <time_frame>day 0,14,28,42</time_frame>
    <description>Simple Clinical Colitis Activity Index Partial Mayo score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucosal appearance at sigmoidoscopy</measure>
    <time_frame>week 0,14,28.42</time_frame>
    <description>endoscopic disease activity Mayo score and possible damage by device</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Ulcerative Colitis</condition>
  <condition>Proctitis</condition>
  <arm_group>
    <arm_group_label>Photopill treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Photopill treatment</intervention_name>
    <arm_group_label>Photopill treatment</arm_group_label>
    <other_name>Photopill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with Ulcerative Proctitis (Mayo grade 1/2)

        Exclusion Criteria:

          -  Symptomatic hemorrhoids

          -  Pregnant or lactating females

          -  Patients that have used any experimental treatment within 8 weeks prior to Day 0

          -  Patient that have used any biologics therapies or immunomodulation agents and/or
             steroids 4 weeks prior to Day 0

          -  Rectal therapy 2 weeks prior to Day 0
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert R D'Haens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>North Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2013</study_first_submitted>
  <study_first_submitted_qc>April 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2013</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Hanke Brandse</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Ulcerative Proctitis</keyword>
  <keyword>Low Level Light Therapy</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Proctitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

